Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma

Signet Ring Cells in Esophageal and GE Junction Carcinomas Have a More Aggressive Biological Behavior

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01824966

Acronym

SRCC

Enrollment

Registered

2013-04-05

Start date

2012-03-31

Completion date

2012-12-31

Last updated

2013-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma, Esophageal Cancer

Keywords

Esophagectomy, Signet Ring Cells

Brief summary

There has been much controversy surrounding the biologic behavior and prognosis of esophageal signet ring cell (SRCs) containing carcinomas. To clarify the biologic behavior of SRCs, the investigators compared the clinicopathologic features and prognosis of SRCs with other adenocarcinomas (ADC) of the esophagus and gastroesophageal junction (GEJ).

Detailed description

Adenocarcinoma (ADC) of the esophagus and gastroesophageal junction (GEJ) is an aggressive neoplasm and has a poor prognosis. Surgical based treatment has been the treatment of choice for localized esophageal adenocarcinoma. Signet-ring cell carcinoma is a unique histologic subtype of adenocarcinoma characterized by abundant intracellular mucin accumulation and a compressed nucleus displaced toward one extremity of the cell (the so-called signet-ring cell (SRC)). According to the World Health Organisation (WHO), a true signet-ring cell carcinoma (SRCca) is defined as an adenocarcinoma in which the predominant component (more than 50% of the tumor) consists of isolated or small groups of SRC in the stroma. If the tumor contains less than 50% of those cells, it is generally considered as an adenocarcinoma (ADC).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- Adenocarcinoma R0 resection Primary surgery

Exclusion criteria

\- Other histology R1 or R2 resection Neoadjuvant therapy

Design outcomes

Primary

Measure	Time frame	Description
Cancer specific 5 year survival in SRCC	from surgery	Cancer specific 5 year survival classified into two groups according to WHO criteria (\>50% SRC or \<50% SRC)

Countries

Belgium

Outcome results